US OptionsDetailed Quotes
CHRS250516C5000
- 0.00
- 0.000.00%
15min DelayClose May 1 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV376.19%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.05Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Coherus BioSciences Stock Discussion
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Monday, 28th April at 10:10 am
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab –
– Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with tori...
Bloody shit. They just want to buy low before reset the actual PT of $7
Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus BioSciences (NASDAQ: CHRS)has announced plans to repurchase approximately $170 million of its 1.500% Convertible Senior Subordinated Notes due 2026 through privately negotiated transactions. The repurchase will be executed at 100% of principal amount plus accrued interest.
The repurchase is contingent on the closing of the previously announced UDENYCA franchise divestiture t...
Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial
Upon the completion of the Udenyca divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,” Coherus CEO Denny Lanfear said in the release. “These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.”
This clinical-s...
No comment yet